Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.33 |
| ▸ | TDO2 | P48775 | 8/20 | 0.33 |
| ▸ | MET | P08581 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20001912 | 0.87 | IDO1 (0.36) | IDO1TDO2 | |
| SCHEMBL20002290 | 0.86 | IDO1 (0.37) | IDO1TDO2 | |
| SCHEMBL20042244 | 0.86 | TDO2 (0.37) | IDO1TDO2 | |
| SCHEMBL20001920 | 0.85 | IDO1 (0.36) | IDO1TDO2 | |
| SCHEMBL20002410 | 0.84 | TDO2 (0.38) | IDO1TDO2 | |
| SCHEMBL20002525 | 0.84 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL20002521 | 0.82 | TDO2 (0.38) | TDO2 | |
| SCHEMBL20042256 | 0.78 | IDO1 (0.31) | IDO1TDO2 | |
| SCHEMBL20002552 | 0.78 | IDO1 (0.31) | IDO1TDO2 | |
| SCHEMBL20002547 | 0.76 | TDO2 (0.34) | TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885MET 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.